相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models
Raghuveer Singh Mali et al.
HAEMATOLOGICA (2021)
Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials
Rita Assi et al.
JOURNAL OF BLOOD MEDICINE (2021)
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W. Pratz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
Stephen S. Y. Lam et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ali Bazarbachi et al.
HAEMATOLOGICA (2020)
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan et al.
LANCET ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
Lindsey T. Brinton et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
Andrew H. Wei et al.
BLOOD (2020)
Quizartinib with Decitabine plus /- Venetoclax Is Highly Active in Patients (Pts) with FLT3-ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial
Musa Yilmaz et al.
BLOOD (2020)
Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study
Naval Daver et al.
BLOOD (2020)
Real-Life Experience of Sorafenib Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML Reveals High Rates of Toxicity-Related Treatment Interruption
Sarah Morin et al.
BLOOD (2020)
Impact of FLT3-ITD length on prognosis of acute myeloid leukemia
Song-Bai Liu et al.
HAEMATOLOGICA (2019)
FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?
Mark J. Levis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
Jun Ma et al.
CLINICAL CANCER RESEARCH (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review
Zabih Warraich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics
Tristan Knight et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
Eunice S. Wang
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Will new agents impact survival in AML?
Jacob M. Rowe
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
Haijiao Zhang et al.
NATURE COMMUNICATIONS (2019)
FLT3 inhibitors in acute myeloid leukemia: Current and future
Christan M. Thomas et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
Kyriaki Tzogani et al.
ESMO OPEN (2019)
Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
Brenda Chyla et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines
Neetu Dayal et al.
FUTURE MEDICINAL CHEMISTRY (2018)
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Ying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
Amanda Tomie Ouchida et al.
CELL DEATH & DISEASE (2018)
FLT3 inhibitors in acute myeloid leukemia
Mei Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial
Andreas Burchert et al.
BLOOD (2018)
Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy
Andrew Wei et al.
BLOOD (2018)
Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML
Richard Thomas T. Maziarz et al.
BLOOD (2018)
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis
Richard M. Stone et al.
BLOOD ADVANCES (2018)
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
Steven Knapper et al.
BLOOD (2017)
Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment
Gabriel Ghiaur et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
Molly M. Gallogly et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2017)
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia
Giorgia Battipaglia et al.
CANCER (2017)
The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells
E. Chang et al.
LEUKEMIA (2016)
Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
Anthony D. Ho et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Andrew M. Brunner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors. Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Zachariah DeFilip et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Jason Gotlib et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
Paolo Strati et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Reasons for optimism in the therapy of acute leukemia
Jacob M. Rowe
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2015)
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Naval Daver et al.
BLOOD (2015)
A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Walter Fiedler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Ahmad Antar et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
C. C. Smith et al.
LEUKEMIA (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
David C. Linch et al.
BLOOD (2014)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
F. Ravandi et al.
LEUKEMIA (2014)
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A. Wander et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
The Receptor Tyrosine Kinase Axl Is Required for Resistance to FLT3-Targeted Therapy in Acute Myeloid Leukemia
Il-Kyoo Park et al.
BLOOD (2014)
Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
Marta Pratcorona et al.
BLOOD (2013)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Ruwanthi N. Gunawardane et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia
Casey B. Williams et al.
PHARMACOTHERAPY (2013)
Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPMI and CEBPA without FLT3-ITD
Gaelle Laboure et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
A. S. Moore et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
Amy E. DeZern et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
Takashi Sato et al.
BLOOD (2011)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia The Start of an Era?
Naveen Pemmaraju et al.
CANCER (2011)
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
Gautam Borthakur et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Sorafenib: a clinical and pharmacologic review
Renuka Iyer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
Roland B. Walter et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang et al.
BLOOD (2008)
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
W. Zhang et al.
LEUKEMIA (2008)
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Rosemary E. Gale et al.
BLOOD (2008)
Antitumor activity of sorafenib in FLT3-driven leukemic cells
D. Auclair et al.
LEUKEMIA (2007)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
Sorafenib (BAY 43-9006) directly targets FLT3-ITD in acute myelogenous leukemia.
Weiguo Zhang et al.
BLOOD (2006)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia
DL Stirewalt et al.
BLOOD (2006)
Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation
Hitoshi Kiyoi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis
M Yanada et al.
LEUKEMIA (2005)
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
RM Stone et al.
BLOOD (2005)
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
W Fiedler et al.
BLOOD (2005)
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
BD Smith et al.
BLOOD (2004)
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell et al.
BLOOD (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
C Thiede et al.
BLOOD (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
M Levis et al.
BLOOD (2002)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
分享论文
